By Colin KellaherSarepta Therapeutics shares jumped more than 25% in premarket trading Monday after a U.S. Food and Drug Administration advisory committee narrowly recommended accelerated approval of the company's SRP-9001 gene therapy for Duchenne muscular dystrophy, or DMD. Shares of the Cambridge, Mass., company, which closed Thursday at $120.20, were recently up nearly 28% at $153.51 in premarket trading. Trading in the stock was halted all day Friday. The FDA, which usually follows the advice of its advisory committees but it isn't bound by the recommendations, has set a May 29 target action date for the application. Write to Colin Kellaher at colin.kellaher@wsj.com(END) Dow Jones NewswiresMay 15, 2023 07:40 ET (11:40 GMT)Copyright (c) 2023 Dow Jones & Company, Inc.

Source: Wall Street Journal May 15, 2023 11:52 UTC